

# BEST AVAILABLE COPY

WDN:SLR 6/14/05 392370.doc  
PATENT

Attorney Reference Number 6907-55924-01  
Application Number 09/729,658

## Remarks

Claims 1-4, 22-26, 41, 42 and 59-71 were pending. By this amendment, claims 72-77 are added, and claims 64, 70 and 71 cancelled without prejudice. Therefore, claims 1-4, 22-26, 41, 42, 59-63, 65-69, and 72-77 are now pending.

Support for the new claims can be found throughout the specification, for example:

Claims 72-73 and 75-76: claims 1, 59 and 65.

Claims 74 and 77: page 72, line 21

Therefore, no new matter is added by this amendment. In addition, no amendments were made to distinguish prior art.

### ***35 U.S.C. § 112, first paragraph, written description***

Claims 68-71 are rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. It is asserted in the Office action that these claims contain new matter. Applicants respectfully disagree and request reconsideration. Even if there is no “literal support” for a method of administering an amount of EDA1-II that is the C-terminal 240 or 211 amino acids or in which E294 has been substituted to a tissue sufficient to promote either hair follicle development, tooth development or sweat gland development, this does not render the language new matter. Indeed, the MPEP states that to satisfy the written description requirement, *ipsis verbis* support (in the same words) is not required for the description to be sufficient. (MPEP§ 2163)

The application does provide the requisite support for the language used in claims 68-71. For example, on page 22, lines 12-18, it is noted that EDA1-II can be mutated at E294, and that assays can be “used to determine whether the mutant peptide retains EDA1-II biological activity, as described in EXAMPLES 19 and 20.” Examples 19 and 20 (starting on page 50), disclose administration of EDA1-II proteins and nucleic acids (including variants or fragments thereof, which would thus include those EDA1-II peptides mutated at E294 or the C-terminal 240 or 211 amino acids of EDA1-II) to subjects to promote hair follicle development, tooth development or sweat gland development. Because the specification provides the requisite support for a method of administering an amount of EDA1-II that is the C-terminal 240 or 211 amino acids or in which E294 has been substituted to a tissue sufficient to promote either hair

BEST AVAILABLE COPY

follicle development, tooth development or sweat gland development, Applicants request that the rejection be withdrawn.

Applicants thank the Examiner for withdrawing the 35 U.S.C. § 112, first paragraph, written description rejection of claims 59-63.

Claims 64, 70 and 71 continue to be rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. Although Applicants respectfully disagree, in order to expedite prosecution, these claims have been cancelled without prejudice to prosecution in a future application.

***35 U.S.C. § 112, first paragraph, enablement***

All of the pending claims continue to be rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement. The Office action recites the factors from *In re Wands*, and concludes that it would require undue experimentation for one skilled in the art to make and use the claimed invention based on the disclosure and information known in the art. Applicants respectfully disagree and request reconsideration.

The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the patent coupled with information known in the art without undue experimentation. As shown by the data presented in the enclosed Rule 132 Declarations<sup>1</sup>, those skilled in the art can practice the method of the pending claims using the teachings in the application, coupled with standard molecular biology techniques.

Based on the teachings and methods provided in the present application, Dr. Pascal Schneider's laboratory conducted experiments and has demonstrated that intraperitoneal administration of 10-20 µg (10-20 mg/kg) of a purified fragment of the human EDA protein (amino acids 239-391) to newborn EDA-

---

<sup>1</sup> Please note that in paragraph 8 of the April 14, 2005 Declaration, the Fc-EDA control used was not exactly the one described in Gaide and Schneider. As noted in paragraph 5 of the June 14, 2005 Declaration, the Fc-EDA control starts at D239 instead of E245 as described in Gaide and Schneider.

deficient (*Tabby*) mice induces the formation of hair on the tail and the formation of sweat glands. This data addresses the concern on page 14 of the Office action that there was no data showing that the effects of EDA1-II can be demonstrated in the actual subject injected. That amino acids 239-391 of EDA1-II can be used to increase hair follicle development and sweat gland development by is disclosed throughout the application (for example see page 16, line 29 – page 17 line 2; page 21, lines 21-25; page 50, lines 21-24; and page 51 lines 13-16). That the protein can be introduced intraperitoneally is disclosed on page 72, line 22 and line 32. The dosage of protein administered falls within the range provided in the specification on page 15, lines 4-12 (0.01 mg/kg to about 1 g/kg body weight). Therefore, the present application provides sufficient teaching to enable one skilled in the art such as Dr. Schneider to practice the claimed method.

The *Tabby* mouse disclosed throughout the specification, and used by Dr. Schneider, is the accepted mouse model for the human disease ectodermal dysplasia. The demonstrated ability of increasing EDA1-II activity to stimulate hair growth and sweat gland development in a subject having an ectodermal disorder (such as the *Tabby* mouse), provides guidance for the application of EDA1-II to humans for the treatment of ectodermal dysplasia. As stated in Paragraph 3 of Dr. Schneider's Rule 132 Declaration dated April 14, 2005, the success of treatment of *Tabby* mice is accepted by those of skill in the art to correlate with results in humans.


In summary, the present application provides detailed teachings which enable those skilled in the art to practice the claimed method of increasing development of ectodermal structures. In view of this data, one skilled in the art would expect that administration of an EDA1-II protein (or a fragment, variant, or fusion thereof that retains EDA1-II biological activity) to a subject (including human subjects) having an ectodermal disorder would increase growth of ectodermal structures, such as hair and sweat glands. Because "data from in vitro or animal testing is generally sufficient to support therapeutic utility" (MPEP § 2107.3), the present claims satisfy the enablement requirement, as data is presented showing a favorable result using the claimed method in a laboratory animal. In view of the arguments and Rule 132 Declarations presented herein, Applicants request that the 35 U.S.C. § 112, first paragraph rejections be withdrawn.

In view of these amendments, and the enclosed Rule 132 Declarations, this amendment places the application in condition for allowance. If there are any minor issues that need to be resolved prior to issuing a Notice of Allowance, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Sherree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 228-9446

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Zonana et al.

Application No. 09/729,658

Filed: December 4, 2000

Confirmation No. 3101

For: HYPOHIDROTIC ECTODERMAL  
DYSPLASIA GENES AND PROTEINS

Examiner: Maria Marvich, Ph.D.

Art Unit: 1636

Attorney Reference No. 6907-55924-01

COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

## DECLARATION UNDER 37 C.F.R. § 1.132

1. I, Dr. Pascal Schneider, am an Assistant Professor in the Department of Biochemistry at the University of Lausanne, in Switzerland. I have over 10 years of molecular biology experience, and over 4 years of experience in the field of Ectodysplasin A (Eda). I am also a co-author of the Gaide and Schneider article (*Nat. Med.* 9:614, 2003). A copy of my CV is attached as Exhibit A.

2. I have read and understand relevant portions of the above-referenced patent application, including the pending claims, and relevant portions of the Office action dated February 14, 2005.

3. *Tabby* mice are the accepted model of human ectodermal dysplasia. *Tabby* mice share many symptoms with human patients because both X-linked hypohidrotic ectodermal dysplasia and *Tabby* phenotypes are caused by mutations of the syntenic Ectodysplasin A (Eda) gene on chromosome X. Therefore, evidence of success of treatment in the *Tabby* mouse is accepted by me and other persons of skill in this field to correlate with results that can be obtained in humans.

4. The method disclosed in the above-referenced patent application has an important role in treating ectodermal disorders, such as disorders that decrease or inhibit hair, tooth or sweat gland development. For example, the method of the pending claims allows one to increased development.

of hair follicles, teeth or sweat glands by increasing EDA1-II activity, such as by administration of an EDA1-II protein (or variant or fragment thereof that retains EDA1-II activity).

5. It is my understanding that in the Office action of February 14, 2005, all of the pending claims, which concern a method of increasing hair follicle, tooth, or sweat gland development, were rejected as not sufficiently enabled by the specification. As shown in FIG. 1 (Exhibit B), results obtained using methods disclosed in the present application demonstrate that EDA1-II proteins can be administered to a subject to increase hair growth. Therefore, the methods disclosed in the present application have been shown by my laboratory to work as described.

6. To demonstrate that increasing EDA1-II biological activity can increase development of ectodermal structures such as hair, the method disclosed in the present application was used to administer an EDA1-II peptide fragment (amino acids 239-391 of EDA1-II) to *Tabby* mice as described in the paragraphs below.


7. The EDA1-II fragment 239-391 was produced in CHO cells using standard molecular biology methods. Briefly, expression constructs containing the human EDA1-II fragment 239-391 were cloned into the PCR3 mammalian expression vector (Invitrogen) using standard molecular biology techniques. The sequence encoding the human EDA1-II protein fragment (amino acids 239-391) was cloned at the 3' of a signal peptide from hemagglutinin (HA signal). The HA signal peptide is removed in the process of secretion, resulting in a mature protein that is a soluble version of human EDA1-II starting at amino acid residue Asp239 that does not contain any non-EDA1-II sequence. CHO cells were transfected with 1.5 µg of plasmid plus 0.5 µg of pEGFP tracer plasmid mixed with 10 µl of Polyfect (Qiagen), according to the manufacturer's instructions. Resulting clones selected with G418 were isolated and expanded. EDA1-II fragment 239-391 secreted into the supernatant was collected after 10 days and subjected to immunoprecipitation followed by anti-EDA Western blotting to confirm expression. For the purification of EDA1-II fragment 239-391, 2 mg of EDAR-Fc was coupled to a 1 ml HiTrap NHS-Sepharose column according to the manufacturer's instructions. Combined elutions of 5 purifications were concentrated to 100 µl in an Amicon Ultra filter device (cut off 10000 Da). Protein concentration was estimated by Western blotting using known amounts of Fc-EDA-1611 protein that had been cleaved to completion with Prescission protease. As Western blot showing the resulting purified EDA1-II fragment 239-391 is shown in


FIG. 2 (Exhibit B). The EDA1-II fragment 239-391 migrates as a doublet, representing N-glycosylated and unglycosylated EDA1-II, respectively.

8. The purified EDA1-II fragment 239-391 was injected intraperitoneally in newborn *Tabby* mice. Homozygous female and hemizygous male *Tabby* mice (Jackson Laboratories, 000314) were injected intraperitoneally at day 1 after birth with a maximal volume of 20  $\mu$ l using a 0.5 ml syringe (U-100 Insulin 0.5 ml, Becton Dickinson). The amount of protein administered was 10 or 20  $\mu$ g (about 10-20 mg/kg). Fc-EDA (described in Gaide and Schneider, *Nat. Med.* 9:614, 2003; referenced in the Office action) was used as a positive control. Photography of tail hairs were performed 2.5 weeks post injection.

9. As shown in FIG. 2 (Exhibit B), EDA1-II fragment 239-391 displays biological activity *in vivo* and induces hair formation in *Tabby* mice. At 2.5 weeks post-injection, mice displayed numerous hairs on the tail, particularly of the ventral face. Although this reversion was less marked than that observed with smaller amounts of Fc-EDA, it is still significant compared to the control *Tabby* mice that received only PBS. In PBS-treated animals, the tail is entirely devoid of hair, and the structure of the skin is altered (FIG. 2). In conclusion, we have generated a fragment of EDA1-II composed exclusively of wild type human EDA1-II sequence and that is able to induce formation of hair on the tail of EDA-deficient animals. This provides further evidence of the role of EDA1-II for the treatment of ectodermal disorders such as X-linked hypohidrotic ectodermal dysplasia.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

  
Dr. Pascal Schneider

  
Date



## CURRICULUM VITAE

Name SCHNEIDER, Pascal  
Date of birth March 29th 1964  
Place of birth Winterthur, Switzerland  
Citizenship Swiss  
Marital status Married, one child  
Address Department of Biochemistry  
University of Lausanne  
Chemin des Boveresses 155  
CH-1066 Epalinges  
Phone ++41-21-692-5709  
Fax ++41-21-692-5705  
e-mail pascal.schneider@unil.ch  
web <http://www.unil.ch/ib/page9496.html>

### EDUCATION AND POSITIONS HELD

2002-present Assistant Professor, at the Department of Biochemistry, University of Lausanne, Switzerland.  
Research project: " TNF family members APRIL, BAFF and EDA".  
Recipient of stipends from the Federal Office of Public Health (1996-2000) and the FNRS (2000-2005). Co-applicant of a NCCR grant (2001-2003) and of a CTI grant (2004-2006).

2001 Privat-Docent, University of Lausanne

1994-2002 Research Assistant at the Institute of Biochemistry, University of Lausanne. Group of Prof. J. Tschopp.  
Research project: " Apoptosis-inducing ligands and receptors".

1992-1994 Post-doctoral long-term EMBO fellow, Department of Biochemistry, University of Dundee, Scotland. Group of Prof. MAJ. Ferguson.  
Research project: " Structure and biosynthesis of glycoconjugates in trypanosomatid parasites".

1988-1992 PhD thesis at the Institute of Biochemistry, University of Lausanne, Switzerland. Thesis directors: Dr C. Bordier and Prof. J. Mauë l.  
Subject: "S tructural and enzymatic characterization of the surface metalloprotease of *Leishmania*"

1984-1988 Licence in Biological Sciences (with one year each biochemistry and organic chemistry certificates), University of Lausanne.

1980-1983 Federal Certificate of Maturity (scientific), Yverdon, Switzerland.

Award

2005 Sero Young Investigator Award for the best recent biotechnology discovery/invention in the Lake of Geneva region





# PUBLICATIONS

79. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner Q-G, Cachero T, Qian F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P (2005) Identification of proteoglycans as APRIL-specific binding partners. *J. Exp. Med.* In press
78. Iordanov, M, Ryabinina OP, Schneider P, Magun BE (2005) Two mechanisms of caspase 9 processing in double-stranded RNA- and virus-triggered apoptosis. *Apoptosis* 10: 153-166
77. Avalos AM, Arthur, WT, Schneider P, Quest AFG, Burridge K, Leyton L (2004) Aggregation of integrins and RhoA activation are required for Thy-1-induced morphological changes in astrocytes. *J Biol Chem* 279, 39139-39145
76. Legler DF, Doucey, M-A, Schneider P, Chapatte F, Bender FC, Bron C (2004) Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. *FASEB J* 19: 73-75
75. Mustonen T, Ilomonen M, Pummila M, Kangas A, Laurikkala J, Jaatinen R, Pispä J, Gaide O, Schneider P, Thesleff I, Mikkola M (2004) Ectodysplasin-A1 promotes placodal cell fate during early morphogenesis of ectodermal appendages. *Development* 131: 4907-4919
74. Tardivel A, Tinel A, Lens S, Steiner Q-G, Sauberli E, Wilson A, Mackay F, Rolink AG, Beermann F, Tschopp J, Schneider P (2004) The antiapoptotic factor Bcl-2 can functionally substitute for the B cell survival but not the marginal zone B cell differentiation activity of BAFF. *Eur. J. Immunol.* 34: 509-518
73. Huard, B, Arlettaz, L, Ambrose, C, Kindler, V, Mauri, D, Roosnek, E, Tschopp, J, Schneider, P, French, L (2004) BAFF production by antigen presenting cells provides T cell costimulation *Int Immunol* 16: 467-475
72. Schneider, K, Kothlow, S, Schneider, P, Tardivel, A, Göbel, T, Kaspers, B, Staehli, P (2004) Chicken BAFF- a highly conserved cytokine that mediates B cell survival *Int. Immunol.* 16: 139-148.
72. Batten, M, Fletcher, C, Ng, LG, Groom, J, Wheway, J, Laâbi, Y, Xin, X, Schneider, P, Tschopp, J, Mackay, CR, Mackay, F (2004) TNF deficiency fails to protect B cell-activating factor belonging to the TNF family transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. *J. Immunol.* 172: 812-822
71. Kuenzi, P, Schneider P, Dobbelaere D (2003) Resistance to Fas/FasL-induced apoptosis in *Theileria parva*-transformed T cells. *J. Immunol* 171: 1224-1231
70. Gaide O, Schneider P (2003) Permanent correction of an inherited ectodermal dysplasia with recombinant EDA. *Nature Medicine* 9: 614-618
69. Brunetti CR, Paulose-Murphy M, Singh R, Qin J, Barrett JW, Tardivel A, Schneider P, Essani K, McFadden G (2003) A secreted high affinity inhibitor of human TNF from Tanapox virus. *PNAS* 100: 4831-4836
68. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D, Dobles M, Hertig S, Hofmann K, Van Vlijmen H, Hsu YM, Burkly LC, Tschopp J, Zheng TS. (2003) Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). *J Biol Chem.* 278: 5444-5454
67. Holler N, Tardivel A, Kovacovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J (2003) Two adjacent trimeric fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. *Mol. Cell. Biol.* 23: 1428-1440

66. Strika MC, Bladergroena BA, Woutersa D, Kisielc W, Hooijberga JH, Verlaanb AR, Hordijkc PL, Schneider P, Hacka CE, Kummer JA (2002) Distribution of the human intracellular serpin protease inhibitor 8 in human tissues. *J. Histochem. Cytochem.* 50: 1443-1454.
65. Rolink AG, Tschopp J, Schneider P, Melchers F (2002). BAFF is a survival and maturation factor for mouse B cells. *Eur J Immunol* 32: 2004-2010
64. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson D, Briand C, Grutter MG (2002). The long form of FLIP is an activator of Caspase-8 at the Fas death-inducing signaling complex. *J Biol Chem* 277: 45162-45171
63. Lowin-Kropf B, Kunz B, Schneider P, Held W (2002). A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. *Eur J Immunol*: 33: 773-782
62. Petit F, Arnoult D, Lelievre JD, Parseval LM, Hance AJ, Schneider P, Corbeil J, Ameisen JC, Estaquier J (2002). Productive HIV-1 infection of primary CD4+ T cells induces mitochondrial membrane permeabilization leading to a caspase- independent cell death. *J Biol Chem* 277: 1477-1487
61. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F (2002). Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. *J Clin Invest* 109: 59-68
60. Werner-Favre C, Bovia F, Schneider P, Holler N, Barnet M, Kindler V, Tschopp J, Zubler RH (2001). IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells. *Eur J Immunol* 31: 243-249
59. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001). BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. *Science* 293: 2108-2111
58. Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, Cachero TG, Finke D, Beermann F, Tschopp J (2001). Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. *J Exp Med* 194: 1691-1697
57. Schneider P, Street SL, Gaide O, Hertig S, Tardivel A, Tschopp J, Runkel L, Alevizopoulos K, Ferguson BM, Zonana J (2001). Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A. *J Biol Chem* 276: 18819-18827
56. Leyton L, Schneider P, Labra CV, Ruegg C, Hetz CA, Quest AF, Bron C (2001). Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites. *Curr Biol* 11: 1028-1038
55. Lecossier D, Bouchonnet F, Schneider P, Clavel F, Hance AJ (2001). Discordant increases in CD4+ T cells in human immunodeficiency virus- infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. *J Infect Dis* 183: 1009-1016
54. Huard B, Schneider P, Mauri D, Tschopp J, French LE (2001). T cell costimulation by the TNF ligand BAFF. *J Immunol* 167: 6225-6231
53. Houimel M, Schneider P, Terskikh A, Mach JP (2001). Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. *Int J Cancer* 92: 748-755
52. Tucker, A.S., Headon, D.J., Schneider, P., Ferguson, B.M., Overbeek, P., Tschopp, J., and Sharpe, P.T. (2000) Edar/Eda interactions regulate enamel knot formation in tooth morphogenesis. *Development* 127: 4691-4700

51. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, MacKay F, Bixler SA, Zafari M, Liu ZY, Woodcock SA, Qian F, Batten M, Madry C, Richard Y, Benjamin CD, Browning JL, Tsapis A, Tschopp J, Ambrose C (2000). BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. *J Exp Med* 192: 129-135
50. Rochat-Steiner V, Becker K, Micheau O, Schneider P, Burns K, Tschopp J (2000). FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. *J Exp Med* 192: 1165-1174
49. Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C, Tschopp J (2000). A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. *J Exp Med* 192: 1677-1684
48. Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J, Wajant H (2000). The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. *J Biol Chem* 275: 32208-32213
47. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J (2000). Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nat Immunol* 1: 489-495
46. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D, Engel J, Tschopp J, Schneider P (2000). Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. *J Immunol Methods* 237: 159-173
45. Bodmer JL, Meier P, Tschopp J, Schneider P (2000). Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. *J Biol Chem* 275: 20632-20637
44. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. *Nat Cell Biol* 2: 241-243
43. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F (2000). BAFF mediates survival of peripheral immature B lymphocytes. *J Exp Med* 192: 1453-1466
42. Thome M, Martinon F, Hofmann K, Rubio V, Steiner V, Schneider P, Mattmann C, Tschopp J (1999). Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase. *J Biol Chem* 274: 9962-9968.
41. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, Tschopp J, Wajant H (1999). TWEAK can induce cell death via endogenous TNF and TNF receptor 1. *Eur J Immunol* 29: 1785-1792
40. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999). BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. *J Exp Med* 189: 1747-1756
39. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999). Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. *J Exp Med* 190: 1697-1710
38. Corradin S, Ransijn A, Corradin G, Roggero MA, Schmitz AA, Schneider P, Mauel J, Vergeres G (1999). MARCKS-related protein (MRP) is a substrate for the Leishmania major surface protease leishmanolysin (gp63). *J Biol Chem* 274: 25411-25418
37. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, Schneider P, Tschopp J, Ware CF (1999). Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. *J Immunol* 162: 6967-6970

36. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998). Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. *Science* 282: 490-493
35. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J (1998). Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. *J Exp Med* 187: 1205-1213
34. Kataoka T, Schroter M, Hahne M, Schneider P, Irmeler M, Thome M, Froelich CJ, Tschopp J (1998). FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. *J Immunol* 161: 3936-3942
33. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmeler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. *J Exp Med* 188: 1185-1190
32. Eberl G, Jiang S, Yu Z, Schneider P, Corradin G, Mach JP (1998). An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells. *Clin Exp Immunol* 114: 173-178
31. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, Tschopp J (1998). MyD88, an adapter protein involved in interleukin-1 signaling. *J Biol Chem* 273: 12203-12209
30. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinel E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J (1997). Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. *Nature* 386: 517-521
29. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J (1997). TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. *Immunity* 7: 831-836
28. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J (1997). Characterization of two receptors for TRAIL. *FEBS Lett* 416: 329-334
27. Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, Peitsch MC, Tschopp J (1997). Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. *J Biol Chem* 272: 18827-18833
26. Irmeler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997). Inhibition of death receptor signals by cellular FLIP. *Nature* 388: 190-195
25. Bodmer JL, Burns K, Schneider P, Hofmann K, Steiner V, Thome M, Bornand T, Hahne M, Schroter M, Becker K, Wilson A, French LE, Browning JL, MacDonald HR, Tschopp J (1997). TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). *Immunity* 6: 79-88
24. Becker K, Schneider P, Hofmann K, Mattmann C, Tschopp J (1997). Interaction of Fas(Apo-1/CD95) with proteins implicated in the ubiquitination pathway. *FEBS Lett* 412: 102-106
23. Schneider P, Treumann A, Milne KG, McConville MJ, Zitzmann N, Ferguson MA (1996). Structural studies on a lipoarabinogalactan of *Crithidia fasciculata*. *Biochem J* 313: 963-971
22. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996). Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. *Science* 274: 1363-1366
21. Treumann A, Lifely MR, Schneider P, Ferguson MA (1995). Primary structure of CD52. *J Biol Chem* 270: 6088-6099

20. Schneider P, Nikolaev A, Ferguson MA (1995). The biosynthesis of GDP-D-arabinopyranose in *Crithidia fasciculata*: characterization of a D-arabino-1-kinase activity and its use in the synthesis of GDP-[5-3H]D-arabinopyranose. *Biochem J* 311: 307-315
19. Sacks DL, Pimenta PF, McConville MJ, Schneider P, Turco SJ (1995). Stage-specific binding of *Leishmania donovani* to the sand fly vector midgut is regulated by conformational changes in the abundant surface lipophosphoglycan. *J Exp Med* 181: 685-697
18. Rolland L, Belkaid M, Seye A, Schneider P, Gentilini M (1995). Detection of serum antibodies against *Leishmania* 94 kDa antigen in visceral and cutaneous leishmaniasis due to *Leishmania infantum*. *Parasite* 2: 13-21
17. Redman CA, Schneider P, Mehlert A, Ferguson MA (1995). The glycoinositol-phospholipids of *Phytomonas*. *Biochem J* 311: 495-503
16. Proudfoot L, Schneider P, Ferguson MA, McConville MJ (1995). Biosynthesis of the glycolipid anchor of lipophosphoglycan and the structurally related glycoinositolphospholipids from *Leishmania major*. *Biochem J* 308: 45-55
15. McConville MJ, Schnur LF, Jaffe C, Schneider P (1995). Structure of *Leishmania* lipophosphoglycan: inter- and intra-specific polymorphism in Old World species. *Biochem J* 310: 807-818
14. Buchmuller-Rouiller Y, Corrandin SB, Smith J, Schneider P, Ransijn A, Jongeneel CV, Mauel J (1995). Role of glutathione in macrophage activation: effect of cellular glutathione depletion on nitrite production and leishmanicidal activity. *Cell Immunol* 164: 73-80
13. Schneider P, Schnur LF, Jaffe CL, Ferguson MA, McConville MJ (1994). Glycoinositol-phospholipid profiles of four serotypically distinct Old World *Leishmania* strains. *Biochem J* 304: 603-609
12. Schneider P, McConville MJ, Ferguson MA (1994). Characterization of GDP-alpha-D-arabinopyranose, the precursor of D-Arap in *Leishmania major* lipophosphoglycan. *J Biol Chem* 269: 18332-18337
11. Schneider P, Rosat JP, Ransijn A, Ferguson MA, McConville MJ (1993). Characterization of glycoinositol phospholipids in the amastigote stage of the protozoan parasite *Leishmania major*. *Biochem J* 295: 555-564
10. Schneider P, Ralton JE, McConville MJ, Ferguson MA (1993). Analysis of the neutral glycan fractions of glycosyl-phosphatidylinositols by thin-layer chromatography. *Anal Biochem* 210: 106-112
9. Schneider P, Glaser TA (1993). Characterization of a surface metalloprotease from *Herpetomonas samuelpessoai* and comparison with *Leishmania major* promastigote surface protease. *Mol Biochem Parasitol* 58: 277-282
8. Schneider P, Glaser TA (1993). Characterisation of two soluble metalloexopeptidases in the protozoan parasite *Leishmania major*. *Mol Biochem Parasitol* 62: 223-231
7. Ramsden JJ, Schneider P (1993). Membrane insertion and antibody recognition of a glycosylphosphatidylinositol-anchored protein: an optical study. *Biochemistry* 32: 523-529
6. McConville MJ, Collidge TA, Ferguson MA, Schneider P (1993). The glycoinositol phospholipids of *Leishmania mexicana* promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis. *J Biol Chem* 268: 15595-15604
5. Bouvier J, Schneider P, Malcolm B (1993). A fluorescent peptide substrate for the surface metalloprotease of *Leishmania*. *Exp Parasitol* 76: 146-155

4. Schneider P, Rosat JP, Bouvier J, Louis J, Bordier C (1992). Leishmania major: differential regulation of the surface metalloprotease in amastigote and promastigote stages. *Exp Parasitol* 75: 196-206
3. Buchmuller-Rouiller Y, Schneider P, Betz-Corradin S, Smith J, Mauel J (1992). 3-amino-1,2,4-triazole inhibits macrophage NO synthase. *Biochem Biophys Res Commun* 183: 150-155
2. Schneider P, Ferguson MA, McConville MJ, Mehlert A, Homans SW, Bordier C (1990). Structure of the glycosyl-phosphatidylinositol membrane anchor of the Leishmania major promastigote surface protease. *J Biol Chem* 265: 16955-16964
1. Bouvier J, Schneider P, Etges R, Bordier C (1990). Peptide substrate specificity of the membrane-bound metalloprotease of Leishmania. *Biochemistry* 29: 10113-10119

### Reviews and book chapters

17. Schneider P (2005). APRIL and BAFF in lymphocyte activation. *Curr. Opinion Immunol.* in press
16. Schneider P. (2004) Tools for activation and neutralization of Fas signaling. In *Fas signaling* (H. Wajant, Ed), 12 pages. Georgetown: Eurekah.com, 2004: <http://www.eurekah.com/abstract.php?chapid=1537&bookid=122&catid=56>
15. Schneider P (2004). Signaling by TNF and related ligands. *Inborn Errors of Development* (C. Epstein, R. Erickson and A. Wynshaw-Boris, Eds), pages 340-358, Oxford University Press.
14. Schneider P, Tschopp J (2003) BAFF and the regulation of B cell survival, *Immunology Letters* 88: 57-62
13. Mackay F, Schneider P, Rennert P, Browning J (2003). BAFF and APRIL: a tutorial on B cell survival, *Annu Rev Immunol*, 21: 231-264
12. Bodmer JL, Schneider P, Tschopp J (2002). The molecular architecture of the TNF superfamily. *Trends Biochem Sci* 27: 19-26
11. Schneider P (2000). Production of recombinant TRAIL and TRAIL receptor:Fc chimeric proteins. *Meth. Enzymol.* 322: 325-345
10. Schneider P, Tschopp J (2000). Apoptosis induced by death receptors. *Pharm Acta Helv* 74: 281-286
9. Schneider P, Tschopp J (2000). Modulation of death receptor signalling. *Programmed Cell Death in Animals and Plants* (J.A. Bryant, S.G. Hughes and J.M. Garland, Eds), pages 31-42, BIOS Scientific Publishers
8. Schneider P, Hoessli D (1999). GPI-containing molecules of pathogenic mycobacteria and protozoa. *GPI-anchored membrane proteins and carbohydrates* chapter 8: 129-165, (D.C. Hoessli and S. Ilangumaran, Eds), R.G. Landes Company, Austin, Texas, USA
7. Treumann A, Güther MLS, Schneider P, Ferguson MAJ (1998). Analysis of the carbohydrate and lipid components of glycosylphosphatidylinositol structures. *Methods in Molecular Biology* 76: 213-235 Glycoanalysis protocols (E.F. Hounsell, ED) Humana Press Inc., Totowa, NJ.
6. Schneider P, Ferguson MA (1995). Microscale analysis of glycosylphosphatidylinositol structures. *Methods Enzymol* 250: 614-630
5. Bouvier J, Schneider P, Etges R (1995). Leishmanolysin: surface metalloproteinase of Leishmania. *Methods Enzymol* 248: 614-633

4. Ferguson MAJ, Brimacombe JS, Cottaz S, Field RA, Güther LS, Homans SW, McConville MJ, Mehlert A, Milne KG, Ralton JE, Roy Y, Schneider P, Zitzmann N (1994). Glycosyl-phosphatidylinositol molecules of the parasite and the host. *Parasitology* 108: S45-S54
3. McConville MJ, Schneider P, Proudfoot L, Masterson C, Ferguson MA (1994). The developmental regulation and biosynthesis of GPI-related structures in Leishmania parasites. *Braz J Med Biol Res* 27: 139-144
2. McConville MJ, Schneider P (1993). Conservation of surface molecules in the trypanosomatids. *Parasitology Today* 9: 316-317
1. Schneider P, Bordier C, Etges R (1992). Membrane proteins and enzymes of Leishmania. *Subcell Biochem* 18: 39-72

## EXHIBIT B




FIG. 1




FIG. 2



PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Zonana et al.

Application No. 09/729,658

Filed: December 4, 2000

Confirmation No. 3101

For: HYPOHIDROTIC ECTODERMAL  
DYSPLASIA GENES AND PROTEINS

Examiner: Maria Marvich, Ph.D.

Art Unit: 1636

Attorney Reference No. 6907-55924-01

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

## DECLARATION UNDER 37 C.F.R. § 1.132

1. I, Dr. Pascal Schneider, am an Assistant Professor in the Department of Biochemistry at the University of Lausanne, in Switzerland. This declaration is a supplement to the Declaration filed with the United States Patent and Trademark Office (PTO) on April 14, 2005 (signed by me on April 14, 2005).

2. The method disclosed in the above-referenced patent application has an important role in treating ectodermal disorders, such as disorders that decrease or inhibit hair, tooth or sweat gland development. For example, the method of the pending claims allows one to increased development of hair follicles, teeth or sweat glands by increasing EDA1-II activity, such as by administration of an EDA1-II protein (or variant or fragment thereof that retains EDA1-II activity).

3. It is my understanding that in the Office action of February 14, 2005, all of the pending claims, which concern a method of increasing hair follicle, tooth, or sweat gland development, were rejected as not sufficiently enabled by the specification. As shown in FIGS. 3 and 4 (Exhibits C and D, respectively), results obtained using methods disclosed in the present application demonstrate that EDA1-II proteins can be administered to a subject to increase hair

growth (FIG. 3) and sweat gland development (FIG. 4). Therefore, the methods disclosed in the present application have been shown by my laboratory to work as described.

4. To demonstrate that increasing EDA1-II biological activity can increase development of ectodermal structures such as hair and sweat glands, the method disclosed in the present application was used to administer an EDA1-II peptide fragment (amino acids 239-391 of EDA1-II) to *Tabby* mice as described in the April 14, 2005 Declaration.

5. Briefly, purified EDA1-II fragment 239-391 was injected intraperitoneally in newborn *Tabby* mice. Homozygous female and hemizygous male *Tabby* mice (Jackson Laboratories, 000314) were injected intraperitoneally at day 1 after birth with a maximal volume of 20  $\mu$ l using a 0.5 ml syringe (U-100 Insulin 0.5 ml, Becton Dickinson). The amount of protein administered was 10 or 20  $\mu$ g (about 10-20 mg/kg). Fc-EDA (similar to that described in Gaide and Schneider, *Nat. Med.* 9:614, 2003; referenced in the Office action, in which EDA1-II starts at D239 instead of E245 in order to provide a better control for EDA1-II fragment 239-391) was used as a positive control. Photography of tail hairs were performed 10 weeks post-injection. Sweat gland formation was analyzed 10 weeks post injection.

6. As shown in FIG. 3 (Exhibit C), EDA1-II fragment 239-391 displays biological activity *in vivo* and induces hair development in *Tabby* mice. At 10 weeks post-injection, *Tabby* mice administered the EDA1-II fragment 239-391 (or the Fc-EDA control) displayed numerous hairs on the tail (arrows indicate the presence of hair), particularly of the ventral face. In PBS-treated animals, the tail is entirely devoid of hair, and the structure of the skin is altered (FIG. 3). An untreated *Tabby* mouse and an untreated wild type mouse are shown in FIG. 3 as negative and positive controls, respectively.

7. Sweat gland formation was determined as follows. Hind paws of immobilized animals were painted with a solution of 3% (w/v) iodine in ethanol. Once dry, the paws were painted with a suspension of 40% (w/v) of starch in mineral oil. Sweat was detected as dark spots and pictures of the paws were taken using a digital camera. The rationale for the sweat test is as follows. Iodine binds starch. In an aqueous environment, the complex displays a very dark

color. Iodine and starch are first spread on the skin, in the absence of water. The stress generated by handling the mouse is then sufficient to induce sweat. This provides water at the exit of the sweat gland, and in this region the black complex between iodine and starch is revealed.

8. Results of the sweat tests were performed on the same mice shown in FIG. 3. Sweat is detected as dark spots, mainly on the cushions and at the toetips. In each case, the detail of one cushion is also shown (FIG. 4). As shown in FIG. 4 (Exhibit D), EDA1-II fragment 239-391 displays biological activity *in vivo* and induces sweat gland development in *Tabby* mice. Untreated *Tabby* mice (and *Tabby* mice injected with PBS) have no sweat glands, while *Tabby* mice administered EDA1-II fragment 239-391 (EDA) or Fc-EDA have one or more sweat glands. Arrows point at characteristic sweat glands. An untreated *Tabby* mouse and an untreated wild type mouse are shown as negative and positive controls, respectively.

9. In conclusion, we have generated a fragment of EDA1-II composed exclusively of wild type human EDA1-II sequence and that is able to induce formation of hair on the tail of EDA-deficient animals and to induce formation of sweat glands in EDA-deficient animals. This provides further evidence of the role of EDA1-II for the treatment of ectodermal disorders such as X-linked hypohidrotic ectodermal dysplasia.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

  
Dr. Pascal Schneider

June 14, 2005  
Date

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**